Jim Simons
CADL icon

Jim Simons’s Candel Therapeutics CADL Stock Holding History

Jim Simons’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,780
Closed -$62.6K – 3227
2026
Q1 		$62.6K Buy
+12,780
New +$69.5K ﹤0.01% 3088
2025
Q3 		– Sell
-163,600
Closed -$828K – 3532
2025
Q2 		$828K Buy
+163,600
New +$842K ﹤0.01% 2597
2024
Q3 		– Sell
-20,600
Closed -$128K – 3548
2024
Q2 		$128K Sell
20,600
-36,305
-64% -$272K ﹤0.01% 3140
2024
Q1 		$90K Buy
56,905
+38,230
+205% +$56.8K ﹤0.01% 3390
2023
Q4 		$27K Buy
+18,675
New +$18.1K ﹤0.01% 3543
2023
Q3 		– Sell
-12,800
Closed -$16K – 3696
2023
Q2 		$16K Sell
12,800
-8,200
-39% -$12.1K ﹤0.01% 3795
2023
Q1 		$28K Buy
+21,000
New +$41K ﹤0.01% 3766

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Portolan Capital Management
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jim Simons's CADL Position: Q2 2026 in Review

Jim Simons sold out of Candel Therapeutics (CADL) in Q2 2026, closing a stake of 12,780 shares — an estimated $62.6K sold.

Jim Simons first reported a position in CADL in Q1 2023 and held it in 7 quarters. The position peaked at $828K in Q2 2025. 137 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Jim Simons reported no remaining Candel Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jim Simons sold 12,780 Candel Therapeutics shares in Q2 2026, an estimated $62.6K.
  • Jim Simons first reported a position in Candel Therapeutics in Q1 2023 and held it in 7 quarters.
  • Jim Simons's Candel Therapeutics position peaked at $828K in Q2 2025.
  • 137 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.